RAPP (Rapport Therapeutics) Insider Ownership: 4.29 % (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $40.68
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Insider Ownership?

Rapport Therapeutics RAPP -1.69% 14 Insider Ownership is 4.29 % as of Jul. 24, 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rapport Therapeutics's insider ownership is 4.29%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rapport Therapeutics's Institutional Ownership is 113.55%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rapport Therapeutics's Float Percentage Of Total Shares Outstanding is 63.07%.

Rapport Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Insider Ownership Chart

Rapport Therapeutics Historical Data

The historical data trend for Rapport Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 6.09 6.07 6.05 4.73 4.70 4.52 4.49 4.48 4.33 4.29
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 4.29 % mean?
Rapport Therapeutics (RAPP) has a Insider Ownership of 4.29 % as of Jul. 24, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Insider Ownership too high?
Rapport Therapeutics' current Insider Ownership is 4.29 %. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Insider Ownership compare to SION and TYRA?
Rapport Therapeutics' Insider Ownership of 4.29 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Insider Ownership is 4.29 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Insider Ownership of 4.29 %. The current Insider Ownership is 4.29 %. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Insider Ownership is 4.29 % as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.68
Price